| scholarly article | Q13442814 |
| P50 | author | Tammie L. Benzinger | Q56154010 |
| Brian A Gordon | Q56816939 | ||
| David M. Holtzman | Q56827171 | ||
| John C. Morris | Q56839763 | ||
| Anne M Fagan | Q66909797 | ||
| Tyler Blazey | Q88144739 | ||
| P2093 | author name string | Yi Su | |
| P2860 | cites work | Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 |
| Suspected non-Alzheimer disease pathophysiology--concept and controversy | Q26771270 | ||
| Neuropathological stageing of Alzheimer-related changes | Q27860862 | ||
| Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade | Q29614407 | ||
| Automatically parcellating the human cerebral cortex | Q29615077 | ||
| The Clinical Dementia Rating (CDR): current version and scoring rules | Q29616280 | ||
| Clinical and biomarker changes in dominantly inherited Alzheimer's disease | Q29619940 | ||
| Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers | Q29620245 | ||
| Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria | Q30458193 | ||
| Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease | Q30557788 | ||
| Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement | Q30572288 | ||
| Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition | Q33559175 | ||
| Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration | Q33581412 | ||
| Correction for partial volume effects in PET: principle and validation | Q34468480 | ||
| Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults | Q34922621 | ||
| Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. | Q34940642 | ||
| Quantitative analysis of PiB-PET with FreeSurfer ROIs | Q35040068 | ||
| Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study | Q35073049 | ||
| Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression | Q35106472 | ||
| Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease | Q35195654 | ||
| Hyperphosphorylated tau in young and middle-aged subjects | Q35644063 | ||
| So what if tangles precede plaques? | Q35785696 | ||
| Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease | Q35948528 | ||
| Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease | Q36408912 | ||
| An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease | Q36650399 | ||
| Brain injury biomarkers are not dependent on β-amyloid in normal elderly | Q36863815 | ||
| Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI | Q37027184 | ||
| The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals | Q37090083 | ||
| Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage | Q37237863 | ||
| Mild cognitive impairment due to Alzheimer disease in the community | Q37245465 | ||
| Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity | Q37291586 | ||
| Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease | Q37314982 | ||
| Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia | Q37351280 | ||
| Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis | Q37448226 | ||
| Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study | Q37524511 | ||
| Alzheimer disease: Aβ-independent processes-rethinking preclinical AD. | Q37604297 | ||
| Partial volume correction in quantitative amyloid imaging | Q41716835 | ||
| NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers | Q42630406 | ||
| Preclinical AD predicts decline in memory and executive functions in subjective complaints | Q44696255 | ||
| Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain | Q44810166 | ||
| Neuropathology of cognitively normal elderly | Q48125911 | ||
| Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease | Q48266934 | ||
| Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease | Q48442778 | ||
| Classification of non-demented patients attending a memory clinic using the new diagnostic criteria for Alzheimer's disease with disease-related biomarkers | Q48609740 | ||
| Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease | Q48771556 | ||
| Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. | Q48963534 | ||
| Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. | Q51986028 | ||
| Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. | Q53212473 | ||
| The pathological process underlying Alzheimer's disease in individuals under thirty | Q82953907 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| pathophysiology | Q1135939 | ||
| P304 | page(s) | 1192-1200 | |
| P577 | publication date | 2016-08-22 | |
| P1433 | published in | JAMA Neurology | Q276813 |
| P1476 | title | Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology | |
| P478 | volume | 73 |
| Q90043569 | A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials |
| Q50420116 | Age-accelerated cognitive decline in asymptomatic adults with CSF β-amyloid |
| Q38812890 | Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study |
| Q38893744 | Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology |
| Q90351471 | Alzheimer Disease: An Update on Pathobiology and Treatment Strategies |
| Q88503397 | Alzheimer disease: Preclinical Alzheimer disease - the new frontier |
| Q47980580 | Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia |
| Q51154144 | Association of Neuropathological Markers in the Parietal Cortex With Antemortem Cognitive Function in Persons With Mild Cognitive Impairment and Alzheimer Disease. |
| Q64934926 | Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau. |
| Q50103609 | Biomarker-based diagnostics of Alzheimer's disease : Concept of suspected non-Alzheimer pathology |
| Q91046010 | Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction |
| Q47587631 | Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry |
| Q55003313 | Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology. |
| Q50321758 | Defining SNAP by cross-sectional and longitudinal definitions of neurodegeneration |
| Q92201851 | Detecting Non-cognitive Features of Prodromal Neurodegenerative Diseases |
| Q92265910 | Dissociable age and memory relationships with hippocampal subfield volumes in vivo:Data from the Irish Longitudinal Study on Ageing (TILDA) |
| Q92587499 | Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes |
| Q90362067 | Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network |
| Q38683683 | Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology |
| Q39373058 | Hippocampal shape alterations are associated with regional Aβ load in cognitively normal elderly individuals |
| Q61809971 | Impact of Apolipoprotein E gene polymorphism during normal and pathological conditions of the brain across the lifespan |
| Q89688294 | Is tau in the absence of amyloid on the Alzheimer's continuum?: A study of discordant PET positivity |
| Q64385732 | Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. |
| Q89626406 | Longitudinal Amyloid-β PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration |
| Q52589491 | NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. |
| Q88505466 | Neuropsychological Profiles and Trajectories in Preclinical Alzheimer's Disease |
| Q41566620 | Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease |
| Q47324557 | Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease. |
| Q64108768 | Sex differences in the association between amyloid and longitudinal brain volume change in cognitively normal older adults |
| Q89646590 | Spatial navigation ability predicts progression of dementia symptomatology |
| Q47641780 | The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimer's Pathology: A Brief Report |
| Q37690637 | The Function of the Mitochondrial Calcium Uniporter in Neurodegenerative Disorders. |
Search more.